Catena Biosciences
CatenaBio is a biotechnology company focused on developing next-generation protein conjugation technologies for novel therapeutics, especially in oncology. Their proprietary CysTyr® platform enables the fusion of biomolecules in any structure or orientation, allowing for the creation of multi-payload conjugates with unprecedented flexibility, stability, and therapeutic potential. The company's mission is to revolutionize antibody-drug conjugates (ADCs) by enabling the attachment of multiple payloads of any size and complexity to a single antibody, leading to improved efficacy and safety in cancer treatment.
Industries
Nr. of Employees
small (1-50)
Products
Multi-payload antibody-drug conjugate program (preclinical lead targeting TROP2)
A preclinical antibody-drug conjugate program employing site-specific multi-payload conjugation (flexible DAR configurations) targeting TROP2, reported to show improved efficacy and tolerability in preclinical tumor models.
Multi-payload antibody-drug conjugate program (preclinical lead targeting TROP2)
A preclinical antibody-drug conjugate program employing site-specific multi-payload conjugation (flexible DAR configurations) targeting TROP2, reported to show improved efficacy and tolerability in preclinical tumor models.
Services
Collaborative programs to apply site-specific bioconjugation chemistry to partner assets, enabling multi-payload conjugates and novel biotherapeutic constructs.
Collaborative programs to apply site-specific bioconjugation chemistry to partner assets, enabling multi-payload conjugates and novel biotherapeutic constructs.
Expertise Areas
- Protein bioconjugation chemistry
- Antibody-drug conjugate (ADC) design
- Engineered enzyme development for site-specific coupling
- Preclinical oncology model evaluation
Key Technologies
- Enzyme-catalyzed tyrosine–cysteine coupling
- Site-specific bioconjugation
- Antibody-drug conjugates (ADCs)
- Cleavable linker chemistry
News & Updates
Showcasing a novel conjugation system capable of attaching distinct payloads at different sites to the same antibody, enabling stable single molecule targeted combination therapies, Multi-Payload Conjugates, with a well-defined drug-antibody ratio.
Presentation will include recent data shared at the San Antonio Breast Cancer Symposium showcasing the combination of multiple cell-killing mechanisms in a single MPC® built using the company’s proprietary CysTyr® platform.
Announcing the expansion of its leadership team with Saurabh Johri as Chief Business Officer and Rick Kendall as Chief Scientific Officer.
A publication discussing the development of multi-payload conjugates targeting HER2 and TROP2, demonstrating superior efficacy in preclinical models.
A publication highlighting the potential of multi-payload ADCs to improve therapeutic outcomes.
Research on enzymatic oxidative coupling reactions for modifying cysteine-substituted antibodies.
Showcasing a novel conjugation system capable of attaching distinct payloads at different sites to the same antibody, enabling stable single molecule targeted combination therapies, Multi-Payload Conjugates, with a well-defined drug-antibody ratio.
Presentation will include recent data shared at the San Antonio Breast Cancer Symposium showcasing the combination of multiple cell-killing mechanisms in a single MPC® built using the company’s proprietary CysTyr® platform.
Announcing the expansion of its leadership team with Saurabh Johri as Chief Business Officer and Rick Kendall as Chief Scientific Officer.
A publication discussing the development of multi-payload conjugates targeting HER2 and TROP2, demonstrating superior efficacy in preclinical models.
A publication highlighting the potential of multi-payload ADCs to improve therapeutic outcomes.
Research on enzymatic oxidative coupling reactions for modifying cysteine-substituted antibodies.